200 related articles for article (PubMed ID: 15041712)
1. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.
Argiris A; Brockstein BE; Haraf DJ; Stenson KM; Mittal BB; Kies MS; Rosen FR; Jovanovic B; Vokes EE
Clin Cancer Res; 2004 Mar; 10(6):1956-62. PubMed ID: 15041712
[TBL] [Abstract][Full Text] [Related]
2. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
[TBL] [Abstract][Full Text] [Related]
3. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
[TBL] [Abstract][Full Text] [Related]
5. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
7. Synchronous and metachronous head and neck carcinomas.
Schwartz LH; Ozsahin M; Zhang GN; Touboul E; De Vataire F; Andolenko P; Lacau-Saint-Guily J; Laugier A; Schlienger M
Cancer; 1994 Oct; 74(7):1933-8. PubMed ID: 8082099
[TBL] [Abstract][Full Text] [Related]
8. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
Adelstein DJ; Saxton JP; Rybicki LA; Esclamado RM; Wood BG; Strome M; Lavertu P; Lorenz RR; Carroll MA
J Clin Oncol; 2006 Mar; 24(7):1064-71. PubMed ID: 16505425
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
10. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
Cohen EE; Haraf DJ; List MA; Kocherginsky M; Mittal BB; Rosen F; Brockstein B; Williams R; Witt ME; Stenson KM; Kies MS; Vokes EE
J Clin Oncol; 2006 Jul; 24(21):3438-44. PubMed ID: 16849759
[TBL] [Abstract][Full Text] [Related]
11. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
[TBL] [Abstract][Full Text] [Related]
12. Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
Rodriguez CP; Adelstein DJ; Rybicki LA; Saxton JP; Lorenz RR; Wood BG; Scharpf J; Ives DI
Head Neck; 2012 Nov; 34(11):1517-23. PubMed ID: 22180262
[TBL] [Abstract][Full Text] [Related]
13. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
Argiris A; Haraf DJ; Kies MS; Vokes EE
Oncologist; 2003; 8(4):350-60. PubMed ID: 12897332
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
Kies MS; Haraf DJ; Athanasiadis I; Kozloff M; Mittal B; Pelzer H; Rademaker AW; Wenig B; Weichselbaum RR; Vokes EE
J Clin Oncol; 1998 Aug; 16(8):2715-21. PubMed ID: 9704722
[TBL] [Abstract][Full Text] [Related]
15. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
Chang CL; Yuan KS; Wu SY
Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
[TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease.
Vokes EE; Kies M; Haraf DJ; Mick R; Moran WJ; Kozloff M; Mittal B; Pelzer H; Wenig B; Panje W
J Clin Oncol; 1995 Apr; 13(4):876-83. PubMed ID: 7707114
[TBL] [Abstract][Full Text] [Related]
17. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.
Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516
[TBL] [Abstract][Full Text] [Related]
18. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
19. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.
Vokes EE; Weichselbaum RR; Mick R; McEvilly JM; Haraf DJ; Panje WR
J Natl Cancer Inst; 1992 Jun; 84(11):877-82. PubMed ID: 1375657
[TBL] [Abstract][Full Text] [Related]
20. Noncancer health events as a leading cause of competing mortality in advanced head and neck cancer.
Kwon M; Roh JL; Song J; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
Ann Oncol; 2014 Jun; 25(6):1208-14. PubMed ID: 24669018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
